Effect of Lifestyle Intervention on Metabolic Coronary Heart Disease Risk Factors in Obese Older Adults
Overview
Authors
Affiliations
Background: Coronary heart disease (CHD) risk factors increase with age and body mass index (BMI; in kg/m2). However, whether lifestyle intervention ameliorates metabolic CHD risk factors in obese older adults is unknown.
Objective: The objective was to determine whether lifestyle intervention improves metabolic CHD risk factors in obese older adults.
Design: A 6-mo outpatient randomized controlled trial was conducted in obese (BMI >or= 30) older (>or=65 y) adults randomly assigned to diet and exercise therapy (treatment group; n = 17) or no therapy (control group; n = 10). The main outcomes were CHD risk factors.
Results: Body weight decreased by 8.4% (8.2 kg) in the treatment group; weight did not change significantly (0.7 kg) in the control group (P < 0.001 between groups). Changes between the control and treatment groups, respectively, in waist circumference (1 and -10 cm), plasma glucose (4 and -4 mg/dL), serum triacylglycerols (0 and -45 mg/dL), and systolic (-2 and -10 mm Hg) and diastolic (0 and -8 mm Hg) blood pressure were different (P < 0.05 for all). The number of subjects with the metabolic syndrome decreased by 59% in the treatment group but did not change significantly in the control group (P < 0.05). Serum free fatty acids increased by 10 micromol/L in the control group and decreased by 99 micromol/L in the treatment group (P < 0.05). Changes between the control and treatment groups, respectively, in C-reactive protein (0.8 and -2.5 mg/L) and interleukin 6 (1.6 and -2.4 pg/mL) were different (P < 0.05 for both).
Conclusions: Lifestyle intervention decreases multiple metabolic CHD risk factors simultaneously in obese older adults.
Salawu M, Erakhaiwu J, Bamgboye E, Jalo R, Ogah O, Oyewole O Pan Afr Med J. 2024; 48:98.
PMID: 39492855 PMC: 11530389. DOI: 10.11604/pamj.2024.48.98.40776.
Inoue T, Matsuoka M, Tamashiro M, Arasaki O, Arima H Hypertens Res. 2024; 48(2):744-753.
PMID: 39394516 DOI: 10.1038/s41440-024-01921-2.
Bogaards F, Gehrmann T, Beekman M, Lakenberg N, Suchiman H, de Groot C Nat Commun. 2024; 15(1):7013.
PMID: 39147741 PMC: 11327278. DOI: 10.1038/s41467-024-50693-3.
Obesity pharmacotherapy in older adults: a narrative review of evidence.
Henney A, Wilding J, Alam U, Cuthbertson D Int J Obes (Lond). 2024; .
PMID: 38710803 DOI: 10.1038/s41366-024-01529-z.
Gonzalez-Gil A, Barnouin Y, Celli A, Viola V, Villarreal M, Nava M J Clin Endocrinol Metab. 2024; 110(3):e814-e826.
PMID: 38606934 PMC: 11470114. DOI: 10.1210/clinem/dgae249.